Hospital operator HCA Healthcare (NYSE: HCA) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 4.3% year on year to $19.11 billion. Its non-GAAP profit of $7.15 per share was in line with analysts’ consensus estimates.

Is now the time to buy HCA? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

HCA Healthcare’s first quarter results in 2026 were met with a negative market reaction, despite matching Wall Street’s revenue and profit expectations. Management highlighted that the primary drivers behind the results were a significantly milder respiratory season and the impact of a severe winter storm, both of which depressed patient volumes, especially in admissions and emergency room visits. CEO Samuel Hazen noted, “Compared to the first quarter of last year, our respiratory-related admissions were down 42%.” These volume shortfalls, however, were mostly offset by higher-than-expected benefits from state Medicaid supplemental programs and ongoing cost efficiencies. Management acknowledged the challenging operating environment, especially as payer mix shifts and state program uncertainties introduced variability in performance.

Looking forward, HCA Healthcare’s guidance is shaped by ongoing uncertainty in state Medicaid supplemental payments and the evolving dynamics in the health insurance exchange market. CFO Mike Marks stated that their outlook assumes continued volatility in patient coverage and payer mix, with an estimated $600 million to $900 million adjusted EBITDA impact from exchange-related shifts for the full year. Management remains focused on executing its $400 million resiliency plan and advancing digital transformation, particularly artificial intelligence (AI) initiatives aimed at improving care quality and operational efficiency. While supplemental program approvals, such as in Florida, could provide a significant revenue boost if received, Marks cautioned that the environment remains fluid and will require ongoing adaptation.

Key Insights from Management’s Remarks

Management attributed first quarter performance to depressed seasonal volumes, higher Medicaid supplemental program benefits, and continued investments in digital initiatives and network expansion.

• Respiratory and weather impacts: The absence of a typical respiratory season and a major winter storm led to a sharp decline in respiratory-related admissions (down 42%) and emergency room visits (down 32%), creating a temporary volume shortfall that was most pronounced in January.
• Medicaid supplemental program benefit: HCA received a greater net benefit than anticipated from state Medicaid supplemental payment programs, largely due to approvals and reinstatements in Georgia and Texas, which offset the volume shortfalls but are considered unpredictable and variable by management.
• Payer mix and exchange headwinds: Shifts in the health insurance exchange (ACA) environment led to a 15% year-over-year decline in exchange-equivalent admissions and a corresponding 16% increase in uninsured admissions. Management noted that over half of the uninsured growth was due to patients moving from exchanges.
• Resiliency and AI initiatives: The company advanced its $400 million resiliency plan through cost savings and digital transformation, emphasizing AI-driven programs in clinical documentation, nursing handoff, and case management, which management expects will drive productivity and care quality improvements.
• Capital investment and network expansion: HCA continued to invest in expanding its care network, adding over 4% more sites of care, almost 1% more hospital beds, and 4% additional emergency room capacity year-over-year, while also acquiring urgent care and ambulatory facilities to support long-term growth.

Drivers of Future Performance

Management expects the rest of the year to be shaped by payer mix changes, Medicaid program developments, and execution of operational efficiency efforts.

• Medicaid and payer mix volatility: The company’s outlook depends heavily on the approval and renewal of state Medicaid supplemental programs, such as the pending Florida program, which could significantly impact revenue if approved. Ongoing shifts in the health insurance exchange market and a rising uninsured population add further uncertainty to payer mix and collections.
• Cost discipline and AI adoption: HCA aims to achieve its targeted $400 million in cost savings through its resiliency plan, leveraging digitalization and AI tools to streamline clinical documentation, patient management, and administrative workflows. Management believes this will help mitigate rising labor and supply costs and improve operating leverage as volumes normalize.
• Network and capital deployment: With a multi-year capital pipeline of $5.5 to $6 billion in approved projects, HCA is expanding hospital capacity and outpatient facilities to meet growing demand in core markets. Management sees these investments as critical for maintaining market share and supporting future volume growth.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be closely watching (1) approval and timing of the Florida Medicaid supplemental program, which could materially affect revenue, (2) continued execution and measurable results from HCA’s $400 million resiliency and AI-driven cost savings initiatives, and (3) stabilization of payer mix and uninsured trends as the health insurance exchange environment remains unsettled. Progress on network expansion projects and outpatient acquisitions will also be key indicators of sustainable growth.

HCA Healthcare currently trades at $433.58, down from $474.03 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.